Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
321.20    0.30 (0.09%)
Bid:
320.40
Ask:
320.50
Spread: 0.10 (0.031%)
Market Cap: £28.42b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Director/PDMR Shareholding

20 Jul 2022 17:45

RNS Number : 2030T
Haleon PLC
20 July 2022
 

HALEON PLC

 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

20 July 2022

Notification and Public Disclosure in accordance with the requirements of The EU Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMR") and Persons Closely Associated with them.

On 19 July 2022, Haleon plc (the "Company") received notification of the following transaction as detailed below.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Vindi Banga

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Senior Independent Director - Person Discharging Managerial Responsibilities

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Haleon plc

b)

 

LEI

 

549300PSB3WWEODCUP19

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Haleon plc Ordinary shares of £1.25 each (to be reduced to 1 pence following Haleon plc's capital reduction -please refer to the Prospectus for more information on the capital reduction).

Identification code

ISIN Code: GB00BMX86B70

b)

 

Nature of the transaction

 

 

Ordinary shares received in the Company on 19 July 2022, in accordance with the terms of the demerger from GSK as disclosed in the Company's prospectus dated 1 June 2022.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

n/a

71,800

d)

 

Aggregated information

- Aggregated volume

71,800

- Price

n/a

e)

 

Date of the transaction

 

19 July 2022

f)

 

Place of the transaction

 

London Stock Exchange

 

 

Amanda Mellor

Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBLGDRDDDDGDG
Date   Source Headline
1st May 202411:10 amRNSDirectorate Change
1st May 20247:00 amRNSHaleon 2024 Q1 Trading Statement
24th Apr 20247:00 amRNSAppointment of Dawn Allen as CFO
12th Apr 202412:00 pmRNSNotice of Annual General Meeting (AGM)
3rd Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 20249:15 amRNSTotal Voting Rights and Capital
22nd Mar 202411:30 amRNSHolding(s) in Company
21st Mar 20246:00 pmRNSHaleon
21st Mar 20244:38 pmRNSTotal Voting Rights and Capital
21st Mar 20244:05 pmRNSClosing of Secondary Global Offering by Pfizer
20th Mar 20248:39 amRNSFinal prospectus supplement filed with the SEC
19th Mar 20247:00 amRNSPricing and upsize of Secondary Global Offering
18th Mar 202411:00 amRNSPreliminary prospectus supplement filed with SEC
18th Mar 20247:00 amRNSProposed Secondary Global Offering by Pfizer Inc.
15th Mar 20243:00 pmRNSPublication of Annual Report and Form 20-F 2023
14th Mar 20244:20 pmRNSDirector/PDMR Shareholding
12th Mar 20243:30 pmRNSDirector/PDMR Shareholding
5th Mar 20242:30 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSHaleon Preliminary 2023 Full Year Results
2nd Feb 20242:15 pmRNSDirector Declaration
25th Jan 20247:00 amRNSHaleon to sell ChapStick
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20246:00 pmRNSHaleon
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
19th Dec 20231:00 pmRNSDirector/PDMR Shareholding
13th Dec 202310:30 amRNSDirector/PDMR Shareholding
10th Nov 20231:00 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:00 amRNSHaleon 2023 Q3 Trading Statement
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20233:00 pmRNSDirector/PDMR Shareholding
10th Oct 202311:00 amRNSHolding(s) in Company
6th Oct 20236:00 pmRNSHaleon
6th Oct 20232:30 pmRNSDirector/PDMR Shareholding
28th Sep 202311:00 amRNSDirector Declaration
13th Sep 20239:30 amRNSDirector/PDMR Shareholding
10th Aug 20231:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20237:00 amRNSHaleon Half Year Results 2023
13th Jul 202311:00 amRNSDirector/PDMR Shareholding
12th Jun 20231:00 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
16th May 20232:00 pmRNSHolding(s) in Company
12th May 20235:30 pmRNSHaleon
12th May 20234:30 pmRNSDirector/PDMR Shareholding
12th May 20239:30 amRNSEMTN programme publication of base prospectus
9th May 20235:00 pmRNSDirector/PDMR Shareholding
3rd May 20237:00 amRNS2023 Q1 Trading Statement
2nd May 20234:00 pmRNSDirector/PDMR Shareholding
20th Apr 20235:30 pmRNSResults of Haleon 2023 Annual General Meeting
20th Apr 20237:00 amRNS2023 AGM trading update
14th Apr 202312:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.